{
    "nctId": "NCT03033186",
    "briefTitle": "Everolimus TDM to Predict Long Term Toxicity",
    "officialTitle": "Foreseeing the Moments of Occurrence of Everolimus Long-term Side Effects by Follow up of Trough Blood Concentrations",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, Renal Cell Carcinoma, Pancreatic Neuroendocrine Tumour, Gastrointestinal Neuroendocrine Tumour, Neuroendocrine Neoplasm of Lung",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Everolimus TDM to predict long-term toxicity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients currently treated with everolimus for any type of cancer, such as the EMA registered indications i.e. advanced (Hormone-Receptor \\[HR\\]-positive, HER2-negative) breast cancer, metastatic renal cell carcinoma (mRCC) or neuroendocrine tumour (NET) of pancreatic, gastrointestinal or lung origin.\n* Aged 18 or above\n* Able and willing to sign the informed consent\n\nExclusion Criteria:\n\n* No informed consent\n* Alactasia",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}